Madison Scientific

NeuroTech Innovation: Opportunities, Trends, and What's Next

About this Event

NeuroTechnology is emerging as one of the most compelling areas of innovation, combining breakthroughs in neuroscience, artificial intelligence, medical devices, and precision medicine to transform the diagnosis and treatment of neurological disorders. Join us for an executive panel discussion featuring experienced investors and entrepreneurs who are actively building and investing in the NeuroTech ecosystem.

Discussion Topics:
  • Why NeuroTech is attracting increased attention from investors and venture capital
  • Emerging technologies reshaping the treatment of neurological disorders
  • The role of AI, brain-computer interfaces, neurostimulation, and digital therapeutics
  • Key trends, opportunities, and challenges facing the NeuroTech sector
  • How experienced investors evaluate NeuroTech companies and platforms
  • Where the panel sees the greatest opportunities over the next five years

Featured Panelists
  • Tyler Wanke, MD, MBA: MedTech investor, entrepreneur, and CEO & Co-Founder of Madison Scientific (MadSci). Tyler invests as an angel and through his family office and has co-founded multiple medical device companies. He is also an adjunct professor at Northwestern University, teaching medical technology innovation and entrepreneurship.
  • John Probst, PHD., MBA: Co-Founder and General Partner of Ground Effect Ventures and an experienced neurotech investor. Previously with Nexus NeuroTech Ventures, Verily, and Apple, where he helped bring Apple Watch from prototype to production. John holds a PhD in Biomedical Engineering and an MBA.
  • Edward Ruppel, MSE: Co-Founder and General Partner of Ground Effect Ventures with deep experience investing in and developing breakthrough medical technologies. Previously with Nexus NeuroTech Ventures, Deerfield Catalyst, and Coridea, where he helped develop devices across 15+ portfolio companies, including first-in-class neuromodulation therapies.

Sign up today to hear how these leaders assess one of healthcare’s fastest-growing sectors and where they believe the next generation of NeuroTech innovation is headed.

Video On Demand

– Recorded

August 11

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.